Belharra Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Belharra Therapeutics's estimated annual revenue is currently $5.7M per year.(i)
  • Belharra Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Belharra Therapeutics has 74 Employees.(i)
  • Belharra Therapeutics grew their employee count by 17% last year.

Belharra Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Scientific OfficerReveal Email/Phone
4
Interim Chief Business OfficerReveal Email/Phone
5
SVP, BiologyReveal Email/Phone
6
VP ProteomicsReveal Email/Phone
7
VP FinanceReveal Email/Phone
8
VP, Head ChemistryReveal Email/Phone
9
SVP, Head BiologyReveal Email/Phone
10
VP, People & OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Belharra Therapeutics?

Belharra Therapeutics, Inc. is a privately held drug discovery company whose novel photoaffinity-based chemoproteomics platform is disrupting the drug discovery paradigm. Guided by a diverse team of biotech trailblazers, Belharra’s proprietary noncovalent drug discovery engine is uniquely capable of identifying novel starting points for transformative medicines to address previously impossible-to-treat diseases and conditions. The company’s next generation chemoproteomics platform enables Belharra scientists to identify small molecule drug candidates for any binding site, on any protein, in any conformational state, in any cell type. Originating with Christopher G. Parker, Ph.D. and John Teijaro, Ph.D. at Scripps Research and pioneers in the field of chemical biology and serial biotech founders Benjamin Cravatt, Ph.D. at Scripps Research and Stuart Schreiber, Ph.D. at the Broad Institute of MIT and Harvard, the four co-founded Belharra Therapeutics in 2021 with a $50M Series A financing from Versant Ventures and incubation at Inception Therapeutics. Belharra is headquartered in the San Francisco Bay Area with its primary lab and offices in San Diego, California.

keywords:N/A

N/A

Total Funding

74

Number of Employees

$5.7M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M743%N/A
#2
$14M74-64%N/A
#3
$9.7M740%N/A
#4
$9.7M74-1%N/A
#5
$9.7M74N/AN/A